Merck is shoring up its drug pipeline with the $1.35 billion buyout of Imago BioSciences, a biotech developing blood and bone marrow disorder therapies that could offer advantages over currently ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. Imago is a clinical stage biopharma company focused on ...

Merck will acquire Imago BioSciences, a pharmaceutical company that focuses on treatments for bone marrow diseases, for $1.35 billion, the drugmaker said Nov. 21. Imago’s main prize is bomedemstat, a ...

Merck announced Monday morning that it is acquiring Imago BioSciences for $1.35 billion. Imago is a clinical stage biopharmaceutical company developing treatments for myeloproliferative neoplasms and ...

Imago Biosciences (US:IMGO) took center stage on Monday, rising 104.5% after noting it had received a takeover offer from pharmaceutical giant Merck (US:MRK) in a deal worth around $1.35 billion.